Novartis (NVS) unveiled 12-month findings from the Phase III APPEAR-C3G trial at the American Society of Nephrology's Kidney Week 2024. These results highlighted that patients with C3 glomerulopathy (C3G) receiving oral Fabhalta (iptacopan) in conjunction with supportive care achieved clinically significant and persistent benefits over one year.
The study demonstrated that Fabhalta administration resulted in noteworthy reductions in proteinuria, noticeable as early as 14 days after treatment commenced and sustained throughout the 12-month period. Furthermore, participants transitioning to Fabhalta during the study's open-label phase also experienced decreased proteinuria levels. An improvement in the estimated glomerular filtration rate (eGFR) slope was observed upon starting Fabhalta, contrasting with patients' prior rapid decline, as evidenced by a prespecified exploratory analysis.
Novartis reported that Fabhalta maintained a favorable safety profile, with no new safety concerns emerging.
